Market Closed -
Deutsche Boerse AG
02:00:59 2023-10-05 EDT
|
5-day change
|
1st Jan Change
|
0.0005
EUR
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: May |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
20.81
|
18.47
|
32.1
|
36.3
|
11.48
|
Enterprise Value (EV)
1 |
16.59
|
16.88
|
30.74
|
36.37
|
12.63
|
P/E ratio
|
-7.46
x
|
-7.51
x
|
-10.2
x
|
-7.9
x
|
-3.02
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
780,440,057
x
|
76,974,562
x
|
240,767,156
x
|
-
|
39,126,407
x
|
EV / Revenue
|
622,272,659
x
|
70,353,793
x
|
230,537,065
x
|
-
|
43,043,762
x
|
EV / EBITDA
|
-10.2
x
|
-8.45
x
|
-13.5
x
|
-11.3
x
|
-3.07
x
|
EV / FCF
|
-19,111,271
x
|
-13,143,595
x
|
-17,379,413
x
|
-18,254,708
x
|
-9,273,652
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
5
x
|
8.15
x
|
9.1
x
|
16
x
|
-36.9
x
|
Nbr of stocks (in thousands)
|
24,485
|
25,307
|
32,758
|
35,938
|
38,909
|
Reference price
2 |
0.8500
|
0.7300
|
0.9800
|
1.010
|
0.2950
|
Announcement Date
|
18-09-28
|
19-09-30
|
20-09-28
|
21-09-28
|
22-09-28
|
Fiscal Period: May |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
0.0267
|
0.24
|
0.1333
|
-
|
0.2934
|
EBITDA
1 |
-1.115
|
-1.629
|
-1.998
|
-2.269
|
-3.212
|
-4.114
|
EBIT
1 |
-1.116
|
-1.681
|
-2.079
|
-2.447
|
-3.594
|
-4.606
|
Operating Margin
|
-
|
-6,303.01%
|
-866.08%
|
-1,835.39%
|
-
|
-1,570.01%
|
Earnings before Tax (EBT)
1 |
-1.116
|
-2.408
|
-2.459
|
-2.607
|
-4.42
|
-3.689
|
Net income
1 |
-1.116
|
-2.408
|
-2.459
|
-2.607
|
-4.42
|
-3.689
|
Net margin
|
-
|
-9,031.44%
|
-1,024.41%
|
-1,955.42%
|
-
|
-1,257.55%
|
EPS
2 |
-0.2980
|
-0.1140
|
-0.0972
|
-0.0960
|
-0.1279
|
-0.0978
|
Free Cash Flow
|
-
|
-0.8683
|
-1.285
|
-1.769
|
-1.993
|
-1.362
|
FCF margin
|
-
|
-3,256.05%
|
-535.27%
|
-1,326.5%
|
-
|
-464.15%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18-04-19
|
18-09-28
|
19-09-30
|
20-09-28
|
21-09-28
|
22-09-28
|
Fiscal Period: Mei |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
0.08
|
1.15
|
Net Cash position
1 |
0.96
|
4.22
|
1.59
|
1.36
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.0234
x
|
-0.2793
x
|
Free Cash Flow
|
-
|
-0.87
|
-1.28
|
-1.77
|
-1.99
|
-1.36
|
ROE (net income / shareholders' equity)
|
-
|
-90.2%
|
-74.8%
|
-90%
|
-152%
|
-377%
|
ROA (Net income/ Total Assets)
|
-
|
-35.7%
|
-35.4%
|
-37.8%
|
-37.8%
|
-62.5%
|
Assets
1 |
-
|
6.748
|
6.948
|
6.906
|
11.68
|
5.904
|
Book Value Per Share
2 |
0.2200
|
0.1700
|
0.0900
|
0.1100
|
0.0600
|
-0.0100
|
Cash Flow per Share
2 |
0.2000
|
0.1700
|
0.0200
|
0.0600
|
0.0400
|
0.0200
|
Capex
1 |
0.1
|
0.11
|
0.25
|
0.79
|
0.27
|
0.03
|
Capex / Sales
|
-
|
398.18%
|
104.15%
|
593.35%
|
-
|
10.26%
|
Announcement Date
|
18-04-19
|
18-09-28
|
19-09-30
|
20-09-28
|
21-09-28
|
22-09-28
|
|
1st Jan change
|
Capi.
|
---|
| +44.36% | 6.29B | | -13.52% | 4.55B | | +10.85% | 3.27B | | -6.52% | 3.23B | | -0.71% | 2.56B | | +51.14% | 2B | | -5.22% | 1.68B | | +1.29% | 1.64B | | +57.69% | 1.6B |
Alternative Medicine
|